Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | GSK3B | P49841 | 2/20 | 0.64 |
| ▸ | APAF1 | O14727 | 1/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ALPL | P05186 | 2/20 | 0.60 |
| ▸ | ALPG | P10696 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ALPP | P05187 | 1/20 | 0.60 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252741 | 0.85 | LMNA (0.60) | LMNATSHRHTTGSK3BAPAF1 | |
| SCHEMBL22965263 | 0.84 | LMNA (0.65) | KDM4ELMNATSHRHTTGSK3B | |
| SCHEMBL27799061 | 0.83 | KDM4E (0.72) | KDM4EHSD17B10APEX1ALDH1A1MEN1 | |
| SCHEMBL15360160 | 0.83 | THRB (0.58) | LMNATSHRHTTGSK3BAPAF1 | |
| SCHEMBL12495433 | 0.83 | ALDH1A1 (0.72) | KDM4EHSD17B10LMNATSHRHTT | |
| SCHEMBL12497263 | 0.83 | LMNA (0.69) | LMNATSHRHTTGSK3BAPAF1 | |
| SCHEMBL14646191 | 0.82 | HSD17B10 (0.94) | KDM4EHSD17B10LMNATSHRHTT | |
| SCHEMBL15643888 | 0.82 | HSD17B10 (1.00) | KDM4EHSD17B10LMNATSHRAPEX1 | |
| SCHEMBL16421959 | 0.81 | KDM4E (0.73) | KDM4EHSD17B10LMNATSHRHTT | |
| SCHEMBL28516010 | 0.81 | LMNA (0.62) | KDM4ELMNATSHRHTTGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058616-A | 2-Substituted-1H-benzimidazole compound, and preparation method and application thereof | 宜昌市中心人民医院(三峡大学第一临床医学院、三峡大学附属中心人民医院) | 2025-05-30 | — | — | CN | disclosed |
| WO-2021023796-A1 | COMPOSITIONS FOR TRANSFECTING A NUCLEIC ACID MOLECULE INTO A CELL COMPRISING HETEROCYCLIC COMPOUNDS GRAFTED TO A CATIONIC POLYMER, AND THEIR APPLICATIONS | POLYPLUS TRANSFECTION (FR) | 2021-02-11 | — | — | WO | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009005551-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1360489-A1 | LOW AFFINITY SCREENING METHOD | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
| WO-2000066573-A2 | OXA COMBINATORIAL LIBRARY, PRODUCTION AND USE THEREOF | CEREP (FR) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | CREBBP, JUN, IRF3 | KDM4E 500/4885HSD17B10 3699/4885LMNA 3970/4885 |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | KDM4E 883/4885HSD17B10 4084/4885LMNA 4724/4885 |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | KDM4E 3447/4885HSD17B10 1901/4885LMNA 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.